Xcell Therapeutics Inc. (KOSDAQ:373110)

Xcell Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	7,764	1,239	5,436	14,632	6,662
Short-Term Investments	35.67	120	120	-	8
Trading Asset Securities	1,002	-	-	-	-
Cash & Short-Term Investments	8,802	1,359	5,556	14,632	6,670
Cash Growth	547.78%	-75.55%	-62.03%	119.39%	701.34%
Accounts Receivable	54.71	282.87	264.4	159.42	26.28
Other Receivables	455.24	333.93	368.52	109.59	384.62
Receivables	509.96	616.8	632.92	269.01	410.9
Inventory	697.92	804.25	686.9	500.67	680.19
Prepaid Expenses	10.6	-	-	-	-
Other Current Assets	491.19	60.41	339.89	22.45	6.22
Total Current Assets	10,512	2,840	7,216	15,425	7,767
Property, Plant & Equipment	4,472	5,355	7,372	7,515	5,773
Long-Term Investments	1,099	34.78	31.69	19.81	7.93
Other Intangible Assets	537.35	125.05	307.51	238.75	247.1
Long-Term Accounts Receivable	-0	-0	-0	-0	0
Other Long-Term Assets	269.81	2,113	582.39	503.45	273.4
Total Assets	16,890	10,468	15,509	23,702	14,068
Accounts Payable	125.57	133.66	90	227.29	464.82
Accrued Expenses	295.36	263.38	277.52	244.79	234.77
Short-Term Debt	3,500	4,000	4,000	4,000	1,400
Current Portion of Long-Term Debt	87.56	72.5	-	-	20
Current Portion of Leases	465.62	589.68	449.1	453.31	413.96
Other Current Liabilities	432.39	383.32	370.56	332.31	3,483
Total Current Liabilities	4,906	5,443	5,187	5,258	6,017
Long-Term Debt	1,132	1,148	870	870	2,821
Long-Term Leases	515.99	695.9	527.77	868.12	252.73
Other Long-Term Liabilities	520.26	510.64	440.67	387.31	3,188
Total Liabilities	7,769	8,085	7,026	7,477	12,683
Common Stock	5,459	4,582	4,380	4,376	1,494
Additional Paid-In Capital	57,993	42,711	39,913	39,860	18,153
Retained Earnings	-55,717	-46,071	-36,835	-28,407	-19,358
Comprehensive Income & Other	1,386	1,162	1,025	395.85	342.59
Total Common Equity	9,121	2,384	8,483	16,225	632.37
Shareholders' Equity	9,121	2,384	8,483	16,225	1,385
Total Liabilities & Equity	16,890	10,468	15,509	23,702	14,068
Total Debt	5,702	6,506	5,847	6,191	4,907
Net Cash (Debt)	3,100	-5,147	-290.75	8,441	1,762
Net Cash Growth	-	-	-	378.96%	-
Net Cash Per Share	309.93	-581.76	-33.21	1019.25	491.75
Filing Date Shares Outstanding	10.92	9.16	8.76	8.28	2.99
Total Common Shares Outstanding	10.92	9.16	8.76	8.28	2.99
Working Capital	5,605	-2,602	2,029	10,167	1,750
Book Value Per Share	835.63	260.10	968.50	1959.16	211.63
Tangible Book Value	8,584	2,258	8,176	15,986	385.27
Tangible Book Value Per Share	786.40	246.46	933.39	1930.33	128.94
Land	370.53	370.53	1,971	1,971	1,971
Buildings	1,624	1,624	1,624	1,624	1,624
Machinery	3,320	3,059	2,952	2,433	2,107
Construction In Progress	-	-	-	278.4	0.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.